FDA declines to approve Corcept's rare disorder drug
As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.
Genmab ends lung cancer drug development
Genmab has decided to stop development of a drug for cancer, acasunlimab for non-small cell lung cancer, following a review of its pipeline.
Vanda ends 40-year hiatus for new motion sickness drugs
The FDA has delivered some end-of-year cheer to Vanda Pharma after approving Nereus, its drug for the prevention of motion sickness.
Insilico ends 2025 with $293m Hong Kong IPO
One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.
Ultragenyx, Mereo's brittle bone drug flames out in trials
Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
10th Tumor Models Summit San Francisco
Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity
The PM Society Careers Event – 18th February 2026
Join us for our popular event to see how your skills and interests could add value to this vital and constantly evolving industry.
Frontiers Health Turns 10
Celebrating a Decade of Innovation and Collaboration in Berlin, November 11–12, 2025 Berlin / November 7th, 2025 | Marking its 10th anniversary,